This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cigna's (CI) Arm Adds Five Digital Health Apps to Its Platform
by Zacks Equity Research
Cigna's (CI) unit bolsters its clinical platform Digital Health Formulary by including five on-line solutions, aiming to relieve people from chronic medical conditions.
3 Reasons to Hold Insulet (PODD) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on Omnipod's continued market access expansion.
Here's Why Investors Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra's (IART) better-than-expected results and the continued demand for its products.
Tandem Diabetes (TNDM) Faces Expense Woes, Macro Issues
by Zacks Equity Research
Factoring in the pandemic and competitive pressure as well as evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) slashes full-year guidance.
Wall Street Analysts Believe AMN Healthcare (AMN) Could Rally 35%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.7% in AMN Healthcare (AMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
AMN Healthcare Services (AMN) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $106.05, marking a -0.55% move from the previous day.
LHC Group's (LHCG) Latest Tie-Up to Improve Patient Services
by Zacks Equity Research
LHC Group's (LHCG) latest JV is expected to expand the availability of vital healthcare services to patients in the comfort of their homes.
Here's Why Investors Should Retain Globus Medical (GMED) For Now
by Zacks Equity Research
Investors are optimistic about Globus Medical's (GMED) better-than-expected results and new product introductions.
Here's Why You Should Retain PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.
CVS Health (CVS) Progresses With Safe Medication Approach
by Zacks Equity Research
A major feature of CVS Health's (CVS) time delay safe function is that it cannot be overridden and is designed to deter pharmacy robbers.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Phirbo (PAHC) Faces Rising Costs and Inflationary Pressure
by Zacks Equity Research
Price competition coming from cheap generic alternatives of a few Phirbo (PAHC) products is a deterrent.
QIAGEN (QGEN) to Develop Companion Diagnostic for Neuron23
by Zacks Equity Research
QIAGEN's (QGEN) novel companion diagnostic assay will help identify individuals who might benefit from Neuron23's drug candidate for Parkinson's disease.
Zacks Industry Outlook Highlights HealthEquity, AMN Healthcare and ModivCare
by Zacks Equity Research
HealthEquity, AMN Healthcare and ModivCare have been highlighted in this Industry Outlook article.
AMN Healthcare and Hudson Technologies have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
AMN Healthcare and Hudson Technologies have been highlighted as Zacks Bull and Bear of the Day.
BD's (BDX) Latest PFS Launch to Boost Production Efficiencies
by Zacks Equity Research
BD's (BDX) newest product offering is expected to set a new standard in performance for vaccine PFS with new and strict specifications for improved production efficiencies.
Haemonetics (HAE) to Offer Two VASCADE Devices in the EU
by Zacks Equity Research
Haemonetics' (HAE) VASCADE and VASCADE MVP devices help patients attain hemostasis more quickly and with lesser complications.
Cardinal Health (CAH) Lowers Medical Segment Income Guidance
by Zacks Equity Research
Cardinal Health (CAH) projects Medical segment loss to be in the range of $25 million to $55 million for the first quarter of fiscal 2023, owing to inventory charges related to the company's gloves portfolio.
Looking for a Growth Stock? 3 Reasons Why AMN Healthcare (AMN) is a Solid Choice
by Zacks Equity Research
AMN Healthcare (AMN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
3 Medical Services Stocks Braving Near-Term Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, AMN and MODV are set to gain the most. However, staffing shortages may disrupt the trend.
3 Reasons to Hold Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Merit Medical's (MMSI) Latest Launch to Boost Patient Care
by Zacks Equity Research
Merit Medical's (MMSI) latest addition to its portfolio is expected to ease access to difficult anatomy in the peripheral vasculature, thereby serving a wider patient pool.
AmerisourceBergen (ABC) to Buy Germany's PharmaLex for $1.3B
by Zacks Equity Research
AmerisourceBergen (ABC) inks a deal to acquire PharmaLex to support its goal to become a strategic partner of choice for pharma customers for clinical and commercial enablement solutions.
Alcon (ALC) Faces Cost Pressure, Supply Chain Disruption
by Zacks Equity Research
Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.
Here's Why Investors Should Retain Syneos Health (SYNH) for Now
by Zacks Equity Research
Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental results.